Translate Bio Inc (NASDAQ:TBIO) has announced that it will be one of the companies presenting at the 34th Annual North American Cystic Fibrosis Conference (NACFC) this year.
The company announced that it will have a poster and oral presentations at the NACFC conference, during which Translate Bio’s presenters will talk about the biopharma’s mRNA Platform. The company already revealed that its presentation will be titled “Delivering CFTR mRNA: An Inhaled, Mutation-agnostic Approach to Treat CF.” The presenter will talk about Translate Bio’s mRNA platform and its potential to deliver highly efficient nucleic acid-based therapies that address cystic fibrosis’ underlying causes.
Last Alert Surged More than 225% in Just ONE DAY!
Get Ready For Our Next Alert
Translate Bio’s presentation will also highlight the unmet needs in cystic fibrosis treatment. It will also touch on the company’s pipeline CF treatment, MRT5005, which is currently in its Phase 1/2 clinical trial. The company also plans to talk about the design of the next generation CF treatments during the NACFC conference. It will be part of the company’s poster and oral presentation titled, “Design of Next Generation CFTR mRNA Therapeutics (MRT) for the Treatment of Patients with Cystic Fibrosis.”
Enrollment for the MRT5005 Phase 1/2 clinical trial
Translate Bio’s presentation at the NACFC conference could not have come at a better time considering that the company recently resumed the enrollment of study subjects in its MRT5005 Phase 1/2 clinical trial. The conference presents a chance for the company to highlight what it is currently working on, and it is a particularly good opportunity to hype up its developments if the mRNA platform is as efficient as advertised.
Translate Bio’s Chief Medical Officer, Dr. Ann Barbier stated that the company was pleased to resume the enrollment. She also noted that patient safety is still the company’s top priority and that the biopharma aims to continue to collaborate with the institutions where the clinical trials are being conducted. The company halted the enrollment of patients into the Phase 1/2 clinical trial in March 2020 due to the coronavirus pandemic. Translate Bio also plans to release an update on the timeline for the release of interim data from the clinical trial.